{"filings":[{"id":106625,"accession_number":"0001104659-26-018582","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics licenses ATX-04 from Duke University for Pompe disease; plans late-stage development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.","Upfront payment plus development, regulatory, and commercial milestone payments; tiered low single-digit royalty on net sales.","Prior Duke clinical study showed ATX-04 improved six-minute walk distance, respiratory muscle strength, and reduced glycogen.","Avenue to assume IND and FDA orphan drug designation for Pompe disease; plans late-stage development leveraging existing data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122956,"accession_number":"0001104659-25-125420","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avenue Therapeutics shareholders elect all six director nominees and ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans, Lindsay Rosenwald.","Ratification of KPMG LLP as independent auditor for FY 2025 passed with 3,862,335 votes for, 104,651 against.","Annual meeting held December 30, 2025; record date November 25, 2025; 3,183,426 common shares and 250,000 Class A Preferred shares eligible.","Broker non-votes: 0 on director election; all votes cast on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122955,"accession_number":"0001437749-25-035624","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Avenue Therapeutics sets Dec 30, 2025 annual meeting; Nov 28 deadline for proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for December 30, 2025; proxy statement to be filed with SEC.","Shareholder proposals for proxy inclusion under Rule 14a-8 must be received by November 28, 2025.","Director nominations and other non-14a-8 proposals also due by November 28, 2025.","All proposals must be submitted in writing to Corporate Secretary at Bay Harbor Islands address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122954,"accession_number":"0001437749-25-034243","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics' subsidiary Baergic Bio acquired by Axsome for up to $82M milestones plus royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.","Sales-based milestones up to $79M; tiered mid-to-high single digit royalty on global net sales of AXS-17 (formerly BAER-101).","Avenue expects to receive ~74% of all future payments and royalties.","Axsome receives worldwide rights to BAER-101 (GABA A PAM) to be evaluated for epilepsy.","CEO granted 443,578 restricted shares; CFO granted 266,147 restricted shares, fully vesting upon closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157238,"accession_number":"0001104659-25-042570","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","1.02","2.01","9.01"],"status":"ready","headline":"Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.","Avenue to receive $2M total within 90 days: $1M due in 30 days, $1M due in 90 days.","Potential future payments: up to $5M development milestones, up to $17M commercial milestones, 1.75% royalty on net sales.","Avenue repurchases 14,777 shares from AnnJi for $1.00 aggregate and pays $0.2M for AnnJi legal expenses.","48-month non-compete for competing products in US, Canada, EU, UK, and Israel after termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175610,"accession_number":"0001104659-25-024505","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.","Delisting due to failure to maintain minimum $2.5M stockholders' equity per Nasdaq Rule 5550(b)(1).","Company failed to meet conditions of Panel exception requiring disclosure of equity-increasing transactions by March 14.","Common stock (ATXI) expected to begin trading on OTC Markets on March 19, 2025.","Company will continue filing periodic reports with SEC but warns of uncertain trading liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175609,"accession_number":"0001437749-25-006685","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.","AnnJi sent termination notice alleging material breaches of AJ201 license; Avenue believes claims are meritless and will contest.","Avenue filed emergency arbitration to block AnnJi from unblinding clinical data in a way that would exhaust irreplaceable samples.","Company must still regain compliance with stockholders' equity requirement; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192555,"accession_number":"0001104659-24-124081","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avenue Therapeutics receives Nasdaq delisting notice for equity deficiency; intends to request hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1.652M as of Sep 30, 2024, below Nasdaq's $2.5M minimum requirement.","Delisting determined due to prior Panel Monitor; company ineligible for 180-day extension submission.","Trading continues; company must request hearing by Dec 3, 2024, to stay delisting.","Company believes equity compliance regained per Q3 10-Q Note 9; will demonstrate at hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192554,"accession_number":"0001437749-24-035304","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics Q3 2024 net loss $3.1M; cash $2.6M; AJ201 data expected year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.1M ($1.92/share) vs net income of $0.5M in Q3 2023.","Cash and equivalents $2.6M at Sep 30, 2024, down $2.3M from Q2 2024.","R&D expenses $2.3M, up from $0.9M in prior year; G&A $0.8M down from $1.2M.","Topline data from AJ201 Phase 1b/2a trial in SBMA expected around year-end 2024.","IV Tramadol Phase 3 safety protocol finalized with FDA; study start subject to financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209022,"accession_number":"0001437749-24-030185","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avenue Therapeutics awards 235,000 RSUs to CEO MacLean and interim CFO Jin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Alexandra MacLean receives 170,000 RSUs; Interim CFO/COO David Jin receives 65,000 RSUs.","RSUs vest in four equal installments on 9/30/24, 12/31/24, 9/20/25, and 9/20/26, subject to continued service.","Settlement deferred until the earlier of Jan 10 after termination of service or a Change in Control.","Awards granted under the company's 2015 Incentive Plan as amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209021,"accession_number":"0001437749-24-025872","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics Q2 2024 net loss $2.7M; AJ201 trial topline data expected H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $4.9M at June 30, 2024, up from $1.8M at Dec 31, 2023.","Net loss $2.7M ($6.43/share) for Q2 2024, compared to $4.0M ($38.74/share) in Q2 2023.","AJ201 Phase 1b/2a SBMA trial last patient visit complete; topline data expected in H2 2024.","Raised $4.4M gross proceeds from April 2024 warrant exercise; 1-for-75 reverse stock split effected.","Regained Nasdaq compliance in May 2024 after reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226869,"accession_number":"0001437749-24-021302","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Avenue Therapeutics stockholders approve 5M share increase to 2015 Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2015 Incentive Plan, increasing authorized shares by 5,000,000.","Plan term extended to June 24, 2034; non-employee director annual limit increased to 500,000 shares.","All six director nominees elected; KPMG ratified as auditor for FY2024.","Total shares reserved under the plan after amendment: 5,070,223."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226868,"accession_number":"0001437749-24-018072","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Avenue Therapeutics regains Nasdaq compliance on equity rule; remains under Panel Monitor until May 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified by Nasdaq on May 21, 2024, that it meets minimum stockholders' equity requirement for continued listing.","Previously disclosed listing matter is now closed.","Subject to a Panel Monitor for one year (through May 21, 2025).","If equity rule is not satisfied during monitoring, loses compliance plan option and must request a hearing.","Company trades as ATXI on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226867,"accession_number":"0001437749-24-016818","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics Q1 net loss $4.3M; $9.4M raised; pipeline progress on AJ201, BAER-101, IV tramadol","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.3M ($15.40/share) vs $7.5M ($101.57) in Q1 2023; R&D $2.4M, G&A $1.3M.","Cash $3.2M at Mar 31, up from $1.8M; additional $4.4M gross proceeds from May 2024 warrant exercise.","AJ201 topline data for Kennedy's Disease expected mid-2024; received FDA agreement on IV tramadol Phase 3 protocol.","Total $9.4M raised from warrant exercises in Jan and May 2024; 1-for-75 reverse split in April to regain Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226866,"accession_number":"0001437749-24-016081","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avenue Therapeutics enters $3.85M ATM equity offering agreement with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered ATM offering agreement with H.C. Wainwright for up to $3,850,000 in common stock sales.","Manager receives 3.0% commission on gross proceeds; Company provides customary indemnification and contribution rights.","Offering is 'at the market' under Rule 415; Company may sell shares at its discretion over time.","Agreement terminates upon sale of all shares or earlier termination by either party on specified prior notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226865,"accession_number":"0001437749-24-014178","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics raises $4.4M via warrant exercise inducement; issues new warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Holders exercised 689,680 existing warrants at reduced price of $6.20/share for $4.4M gross proceeds.","In exchange, Company issued new Series C and Series D warrants to purchase up to 689,680 shares each at $6.20.","Series C warrants exercisable for 5 years; Series D for 18 months; Placement agent got warrants at $7.75.","Proceeds used for general corporate purposes; H.C. Wainwright acted as exclusive placement agent.","Existing warrants (Oct 2022, Nov 2023, Jan 2024) had exercise prices of $116.25, $22.545, and $22.545."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226864,"accession_number":"0001437749-24-013436","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics effects 1-for-75 reverse stock split to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective April 26, 2024; shares reduced from ~44.7M to ~0.6M.","Split is to bring Company into compliance with Nasdaq $1.00 minimum bid price.","No fractional shares; fraction holders get rounded up to next whole share.","Ticker remains ATXI; new CUSIP 05360L403. VStock Transfer is exchange agent.","Holders via brokers need no action; physical certificate holders will receive instructions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245815,"accession_number":"0001437749-24-010044","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq issues delist determination for Avenue Therapeutics; extension to May 20 granted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff issued delist determination on March 26, 2024 for failing Bid Price Rule ($1.00 minimum).","Company did not regain compliance by March 25, 2024 end of 180-day grace period.","Nasdaq Hearings Panel granted extension through May 20, 2024; delist notice has no immediate effect.","Company evaluating options to regain compliance but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245814,"accession_number":"0001104659-24-035544","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics reports FY2023 net loss of $10.5M; AJ201 Phase 1b/2a enrollment complete, topline data Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.5M ($0.98 per share) vs $3.6M loss in FY2022; cash $1.8M as of Dec 31, 2023.","Completed enrollment in AJ201 Phase 1b/2a for SBMA (25 patients); topline data expected Q2 2024.","Reached final agreement with FDA on Phase 3 safety study protocol for IV tramadol; aims to initiate pending financing.","Nasdaq granted extension to May 20, 2024 to meet continued listing requirements.","Raised $5.0M gross in January 2024 via warrant inducement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245813,"accession_number":"0001104659-24-034774","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq panel grants Avenue Therapeutics extension to May 20, 2024 for listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension through May 20, 2024 to meet stockholders' equity and bid price requirements.","Company must evidence closing bid price >= $1.00 for at least 10 consecutive business days by May 20, 2024.","Previously failed to regain compliance by Nov 15, 2023; delisting process had been stayed pending hearing.","No assurance of regaining compliance; company evaluating all available options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245812,"accession_number":"0001104659-24-032401","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avenue Therapeutics stockholders approve reverse stock split in range 30:1 to 75:1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Majority of voting power executed written consent on March 6, 2024, approving reverse stock split.","Board authorized to determine exact ratio between 30-for-1 and 75-for-1.","Holders of approximately 56% of voting power signed consent.","Schedule 14C information statement to be filed with SEC and sent to stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245811,"accession_number":"0001104659-24-027037","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Avenue Therapeutics increases authorized common shares from 75M to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved via written consent on Jan 9, 2024 to increase authorized common shares from 75M to 200M.","Certificate of Amendment filed with Delaware Secretary of State on Feb 20, 2024 effectuating the increase.","No immediate share issuance; increase provides flexibility for future capital raising or strategic transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245810,"accession_number":"0001104659-24-003470","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avenue Therapeutics shareholders approve increase in authorized shares from 75M to 200M and warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Written consent from holders of 56.4% voting power approved Authorized Share Increase to 200M shares.","Issuance of warrants (Jan 5 inducement) exceeding 20% of outstanding common stock authorized.","Authorized common stock increased from 75M to 200M shares via amendment to certificate of incorporation.","Board also approved the share increase, share issuance, and amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245809,"accession_number":"0001104659-24-002318","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics raises $5.0M via warrant exercise; issues new warrants at $0.3006, subject to shareholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.0M from immediate cash exercise of 16.5M existing warrants at reduced exercise price of $0.3006/share.","New unregistered Series A and Series B warrants each to purchase up to 16.5M shares at $0.3006; exercisable only after stockholder approval.","Stockholder approval required to increase authorized shares and comply with Nasdaq Rule 5635(d); no voting rights until exercise.","Maxim Group acted as agent; fees: 3.5% on Jan 2023 warrants and 7.0% on Nov 2023 warrants, plus up to $15,000 expense reimbursement.","Company intends to use net proceeds for general corporate purposes; closing expected on or about January 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263285,"accession_number":"0001104659-23-120977","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avenue Therapeutics receives Nasdaq delisting notice for continued non-compliance with equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Nov 15, 2023 extension deadline.","Staff notified of delisting determination on Nov 20, 2023; company to request hearing to stay delisting.","No immediate effect on trading; stock continues on Nasdaq under ATXI pending hearing outcome.","Company cannot assure that panel will grant continued listing or that compliance can be shown within any extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263284,"accession_number":"0001437749-23-031615","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics reports Q3 net income of $0.5M; cash low, raises $5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $0.5M ($0.06 per share) vs net loss $0.7M in Q3 2022; R&D $0.9M, G&A $1.2M.","Cash $0.2M at Sep 30, 2023; completed $5M public equity offering in Nov 2023.","AJ201 Phase 1b/2a enrollment on track; topline data expected Q2 2024.","BAER-101 preclinical results accepted for AES meeting; IV tramadol Phase 3 design agreed with FDA.","IV tramadol Phase 3 safety study pending additional financing; aim to start as soon as feasible."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263283,"accession_number":"0001104659-23-113772","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics closes $5M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.0M; estimated net proceeds ~$4.1M after placement agent fees and expenses.","Offering of 16,633,400 units at $0.3006/unit; each unit has 1 share (or pre-funded warrant) plus two warrants.","Series A warrants exercisable at $0.3006/share for 5 years; Series B warrants same price for 18 months.","Maxim Group LLC and Lake Street Capital Markets served as placement agents; 8% cash fee (4% for affiliates).","Closing occurred November 2, 2023; proceeds expected for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280478,"accession_number":"0001104659-23-104769","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avenue Therapeutics receives Nasdaq delisting notice for bid price below $1.00 for 30 consecutive days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).","Common stock closed below $1.00 per share for 30 consecutive business days.","Company has 180-day grace period through March 25, 2024 to regain compliance by closing at $1.00+ for 10+ consecutive days.","If not compliant by March 25, 2024, may seek second 180-day period if it meets initial listing criteria and intends to reverse split.","Company will monitor bid price and consider options; no assurance of maintaining listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280477,"accession_number":"0001104659-23-104272","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Avenue Therapeutics enrolls 8th patient in SBMA trial, triggering 276,652 share issuance to AnnJi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled eighth patient in Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy (SBMA).","Issued 276,652 shares of common stock to AnnJi as Second Tranche Shares under license agreement.","Trial is 12-week, multicenter, randomized, double-blind, targeting ~24 patients; primary endpoint safety/tolerability.","AJ201 activates Nrf1/Nrf2 and enhances androgen receptor degradation; previously paid $3M cash and 831,618 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280476,"accession_number":"0001104659-23-099306","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Avenue Therapeutics raises ~$550k in private placement at $0.717/share from Fortress and Rosenwald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 767,085 shares at $0.717/share (Nasdaq closing bid on Sept 7, 2023) to Fortress Biotech and Dr. Lindsay Rosenwald.","No underwriting or placement agent fees incurred; gross proceeds ~$550,000.","Proceeds intended for working capital and general corporate purposes.","Registration rights agreement obligates filing of resale registration statement by September 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280475,"accession_number":"0001437749-23-023068","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics Q2 net loss $4.0M; first AJ201 patient dosed, FDA agrees on tramadol Phase 3 design","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.0M ($0.52 per share) vs $0.6M ($0.41) in Q2 2022; cash $1.6M down from $6.7M at year-end 2022.","First patient dosed in Phase 1b/2a trial of AJ201 for SBMA; topline data expected H1 2024.","BAER-101 preclinical results show full seizure suppression at 0.3 mg/kg in GAERS model; Phase 2a planned for 2024.","FDA alignment on Phase 3 safety study design for IV tramadol; subject to financing, company aims to start soon.","R&D expense surged to $3.0M from $0.2M; G&A $0.9M vs $0.5M, reflecting clinical progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280474,"accession_number":"0001104659-23-083082","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq grants Avenue Therapeutics extension to Nov 15, 2023 for stockholders' equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff granted extension until November 15, 2023 to regain compliance with minimum $2.5M stockholders' equity rule.","Company originally notified of deficiency on May 19, 2023 for not meeting Nasdaq Listing Rule 5550(b)(1).","Company intends to work diligently to regain compliance but cannot assure success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280473,"accession_number":"0001104659-23-078108","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avenue Therapeutics grants options for 1.05M shares to CEO and Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Alexandra MacLean granted option to purchase 800,000 shares at $1.14/share.","Interim CFO/COO David Jin granted option to purchase 250,000 shares at same price.","Options vest in four equal annual installments beginning August 1, 2023.","Options expire 10 years from grant dates (June 29, 2033 and June 30, 2033)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299054,"accession_number":"0001104659-23-074745","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avenue Therapeutics stockholders elect six directors, ratify KPMG, approve say-on-pay at 3-year frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with >9.5M votes each; broker non-votes ~1.37M.","Ratification of KPMG as auditor for FY2023 passed with 10.8M for, 246K against.","Advisory vote on executive compensation approved with 9.5M for, 128K against.","Say-on-pay frequency set at every 3 years on advisory basis (9.4M votes for 3 years).","Meeting held virtually June 22, 2023; quorum achieved with majority voting power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299053,"accession_number":"0001104659-23-063143","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avenue Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Avenue Therapeutics on May 19, 2023, of non-compliance with minimum $2.5M stockholders' equity requirement.","Q1 2023 10-Q reported stockholders' equity of negative $2,157,000.","Company has 45 days (until July 3, 2023) to submit a plan to regain compliance.","No immediate effect on listing; stock continues trading on Nasdaq under ATXI.","Company intends to submit compliance plan and take measures to regain compliance, but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299052,"accession_number":"0001104659-23-059454","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics Q1 net loss $7.5M; advances AJ201 and IV Tramadol programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.5M ($1.37 per share) vs $2.9M loss ($2.05 per share) in Q1 2022.","Cash and equivalents $8.2M at March 31, 2023, up from $6.7M at December 31, 2022.","R&D expenses $1.2M plus $4.2M in licenses acquired (AJ201) vs $1.8M prior-year period.","Entered exclusive license for AJ201 (SBMA treatment); Phase 1b/2a trial ongoing; FDA orphan drug designation.","FDA agreed on most aspects of IV Tramadol safety confirmatory trial protocol; pending final statistical analysis plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299051,"accession_number":"0001104659-23-046174","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics announces FDA agreement on most protocol items for IV Tramadol safety study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received official meeting minutes from FDA Type C meeting on March 9, 2023, for IV Tramadol.","FDA and Avenue agree on majority of proposed protocol items for opioid-induced respiratory depression study vs IV morphine.","FDA agrees a successful study could support complete response to second Complete Response Letter for IV Tramadol.","Company expects to finalize protocol and potentially initiate Phase 3 safety study this year; also planning updates on AJ201 and BAER-101 programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319226,"accession_number":"0001104659-23-039135","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics reports FY2022 net loss of $3.6M; cash $6.7M; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.6M ($1.63/share) vs $3.7M ($3.29/share) in 2021; R&D $2.7M, G&A $5.3M.","Cash $6.7M at Dec 31, 2022, up from $3.8M; raised $12M in Oct 2022 offering and $3.25M in Jan 2023.","In-licensed AJ201 for SBMA (Kennedy's Disease) in Phase 1b/2a; FDA granted Orphan Drug Designation.","IV Tramadol: Type C meeting with FDA in March 2023; update expected in April 2023.","Completed acquisition of Baergic Bio in Nov 2022; appointed Alexandra MacLean to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319225,"accession_number":"0001104659-23-030103","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02","5.08","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics schedules Type C FDA meeting for IV Tramadol; appoints MacLean to board, Kranzler Chairman","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Type C FDA meeting on March 9, 2023 to discuss IV Tramadol respiratory depression study protocol; update expected April 2023.","Board expanded to six; CEO Alexandra MacLean appointed director; Jay Kranzler named Chairman, Lindsay Rosenwald remains director.","Annual meeting set for June 22, 2023; record date April 25, 2023; stockholder proposal deadline March 24, 2023.","FDA previously agreed on study design aspects in August 2022 Type A meeting for IV Tramadol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319224,"accession_number":"0001104659-23-027680","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics licenses AJ201 from AnnJi for SBMA; upfront $3M cash + stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash license fee of $3M ($2M within 60 days, $1M within 180 days).","Issues 831,618 shares initially; up to 276,652 more on 8th patient enrollment in Phase 1b/2a.","Milestone payments up to ~$165M based on net sales; royalties mid-single to low double digits.","AJ201 is in Phase 1b/2a for spinal and bulbar muscular atrophy (Kennedy's Disease); has Orphan Drug Designation.","Exclusive license covers U.S., Canada, EU, UK, Israel for all oral forms except alopecia and Alzheimer's."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319223,"accession_number":"0001104659-23-018503","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Avenue Therapeutics amends bylaws, removes InvaGen special rights, changes quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Second Amended and Restated Bylaws effective February 9, 2023.","Removed all special rights and provisions previously granted to InvaGen Pharmaceuticals Inc.","Quorum for stockholder meetings changed to majority of outstanding voting power.","No immediate financial or operational impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319222,"accession_number":"0001104659-23-010476","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Avenue Therapeutics stockholders approve 55M share increase and 5M share plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved increase in authorized common shares from 20M to 75M (55M increase).","Approved amendment to 2015 Incentive Plan increasing available shares from 266,666 to 5,266,666.","Re-elected all five director nominees: Rosenwald, Charles, Herskowitz, Kranzler, Oltmans.","Ratification of BDO as auditor not voted on due to prior dismissal; KPMG appointed as new auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319221,"accession_number":"0001104659-23-008989","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics closes $3.25M equity raise; existing warrants repriced to $1.55","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$3.25M gross via registered direct offering of 1,940,299 shares and pre-funded warrants, plus private placement of 1,940,299 warrants.","Private placement warrants priced at $0.125 each, exercise price $1.55, 3-year term from initial exercise date; subject to registration.","Existing warrants (exp. Oct 2027) exercise price reduced from $3.30 to $1.55 effective Jan 27, 2023.","Executives, directors and 10%+ holders subject to 90-day lock-up from closing date (Jan 31, 2023).","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319220,"accession_number":"0001104659-23-006536","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Avenue Therapeutics dismisses BDO, engages KPMG as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BDO dismissed as independent auditor effective Jan 21, 2023; prior reports had going concern explanatory paragraph.","No disagreements or reportable events during fiscal years 2021 and 2020 and subsequent interim periods.","KPMG engaged as new independent auditor for fiscal year ending Dec 31, 2022, effective Jan 23, 2023.","No prior consultations with KPMG on accounting principles, disagreements, or reportable events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337439,"accession_number":"0001104659-22-117179","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avenue Therapeutics reports Q3 net loss $0.7M; FDA meeting on IV Tramadol and acquisition of Baergic Bio","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss $0.7M ($0.45/share) vs $0.9M ($0.79/share) in Q3 2021.","Cash $0.2M at Sep 30, 2022 (down from $3.8M at Dec 31, 2021); then raised ~$10.4M net in October offering.","FDA agreed proposed IV Tramadol study design appears reasonable; detailed protocol submission planned.","Completed acquisition of Baergic Bio, adding BAER-101 (GABA-A α2/3 PAM) for refractory epilepsies and panic disorders.","Effected 1-for-15 reverse stock split and closed $12M public offering; regained Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337438,"accession_number":"0001104659-22-115713","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics completes acquisition of Baergic Bio and its CNS asset BAER-101","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Acquired majority of Baergic Bio shares from Fortress Biotech; Baergic now a subsidiary of Avenue.","Baergic's lead compound BAER-101 is a selective GABA-A α2/3 PAM in-licensed from AstraZeneca with safety data in over 700 patients.","Closing conditions included $7.5M equity raise and repurchase of InvaGen's shares in Avenue.","CEO Alexandra MacLean said BAER-101 has potential for orphan and larger CNS indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337437,"accession_number":"0001104659-22-114916","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Avenue Therapeutics completes $3M share repurchase from InvaGen; two directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Completed $3M repurchase of InvaGen's 100% stake in Avenue, financed by public offering closed Oct 11, 2022.","Jaideep Gogtay, M.D. and E. Garrett Ingram resigned from Board and all committees effective Oct 31, 2022.","Resignations not due to any disagreement with Company, its operations, or management.","All rights granted to InvaGen under 2018 Stockholders Agreement terminated upon share repurchase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337436,"accession_number":"0001104659-22-109739","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Avenue Therapeutics regains Nasdaq compliance; bid price and equity requirements satisfied; delisting matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Oct 18, 2022, Nasdaq confirmed Avenue Therapeutics met the $1.00 bid price and $2.5M stockholders' equity requirements for continued listing.","The delisting matter is closed; the company previously faced potential delisting for non-compliance with both requirements.","A Nasdaq Hearings Panel granted a stay through Oct 2022 to demonstrate compliance; company successfully met the conditions.","The company is now in full compliance with all applicable Nasdaq Capital Market listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337435,"accession_number":"0001104659-22-107952","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Avenue Therapeutics closes $12M offering, net $10.4M; uses proceeds to repurchase InvaGen shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten offering of 3,636,365 units at $3.30/unit; net proceeds ~$10.4M.","Proceeds to repurchase all shares held by InvaGen Pharmaceuticals; remainder for working capital.","Believes it now complies with Nasdaq equity requirement (min $2.5M) and bid price >$1.00 for 13 days.","Underwriter Aegis Capital Corp. also purchased 545,454 additional warrants via over-allotment.","Company awaiting formal Nasdaq compliance determination from Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354812,"accession_number":"0001104659-22-104616","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC.","ticker":"ATXI","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq Panel grants Avenue Therapeutics extension to Oct 31 to meet equity requirement, Oct 6 for bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing through Oct 31, 2022 to demonstrate compliance with stockholders' equity minimum of $2.5M.","Company must also satisfy minimum bid price of $1.00 per share by Oct 6, 2022.","Previously, Company was non-compliant with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).","Hearing request on Aug 16, 2022 stayed suspension until Panel decision on Sep 29."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":922590.4210526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-30T23:59:59+00:00|354812"}